Increased lipocalin-2 expression in pulmonary inflammation and fibrosis
Copyright © 2023 Galaris, Fanidis, Tsitoura, Kanellopoulou, Barbayianni, Ntatsoulis, Touloumi, Gramenoudi, Karampitsakos, Tzouvelekis, Antoniou and Aidinis..
Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease with dismal prognosis. The underlying pathogenic mechanisms are poorly understood, resulting in a lack of effective treatments. However, recurrent epithelial damage is considered critical for disease initiation and perpetuation, via the secretion of soluble factors that amplify inflammation and lead to fibroblast activation and exuberant deposition of ECM components. Lipocalin-2 (LCN2) is a neutrophil gelatinase-associated lipocalin (NGAL) that has been suggested as a biomarker of kidney damage. LCN2 has been reported to modulate innate immunity, including the recruitment of neutrophils, and to protect against bacterial infections by sequestering iron.
Methods: In silico analysis of publicly available transcriptomic datasets; ELISAs on human IPF patients' bronchoalveolar lavage fluids (BALFs); bleomycin (BLM)-induced pulmonary inflammation and fibrosis and LPS-induced acute lung injury (ALI) in mice: pulmonary function tests, histology, Q-RT-PCR, western blot, and FACS analysis.
Results and discussion: Increased LCN2 mRNA expression was detected in the lung tissue of IPF patients negatively correlating with respiratory functions, as also shown for BALF LCN2 protein levels in a cohort of IPF patients. Increased Lcn2 expression was also detected upon BLM-induced pulmonary inflammation and fibrosis, especially at the acute phase correlating with neutrophilic infiltration, as well as upon LPS-induced ALI, an animal model characterized by neutrophilic infiltration. Surprisingly, and non withstanding the limitations of the study and the observed trends, Lcn2-/- mice were found to still develop BLM- or LPS-induced pulmonary inflammation and fibrosis, thus questioning a major pathogenic role for Lcn2 in mice. However, LCN2 qualifies as a surrogate biomarker of pulmonary inflammation and a possible indicator of compromised pulmonary functions, urging for larger studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in medicine - 10(2023) vom: 18., Seite 1195501 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Galaris, Apostolos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute lung injury |
|---|
| Anmerkungen: |
Date Revised 20.10.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fmed.2023.1195501 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362425418 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362425418 | ||
| 003 | DE-627 | ||
| 005 | 20231226091222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fmed.2023.1195501 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362425418 | ||
| 035 | |a (NLM)37746070 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Galaris, Apostolos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased lipocalin-2 expression in pulmonary inflammation and fibrosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Galaris, Fanidis, Tsitoura, Kanellopoulou, Barbayianni, Ntatsoulis, Touloumi, Gramenoudi, Karampitsakos, Tzouvelekis, Antoniou and Aidinis. | ||
| 520 | |a Introduction: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease with dismal prognosis. The underlying pathogenic mechanisms are poorly understood, resulting in a lack of effective treatments. However, recurrent epithelial damage is considered critical for disease initiation and perpetuation, via the secretion of soluble factors that amplify inflammation and lead to fibroblast activation and exuberant deposition of ECM components. Lipocalin-2 (LCN2) is a neutrophil gelatinase-associated lipocalin (NGAL) that has been suggested as a biomarker of kidney damage. LCN2 has been reported to modulate innate immunity, including the recruitment of neutrophils, and to protect against bacterial infections by sequestering iron | ||
| 520 | |a Methods: In silico analysis of publicly available transcriptomic datasets; ELISAs on human IPF patients' bronchoalveolar lavage fluids (BALFs); bleomycin (BLM)-induced pulmonary inflammation and fibrosis and LPS-induced acute lung injury (ALI) in mice: pulmonary function tests, histology, Q-RT-PCR, western blot, and FACS analysis | ||
| 520 | |a Results and discussion: Increased LCN2 mRNA expression was detected in the lung tissue of IPF patients negatively correlating with respiratory functions, as also shown for BALF LCN2 protein levels in a cohort of IPF patients. Increased Lcn2 expression was also detected upon BLM-induced pulmonary inflammation and fibrosis, especially at the acute phase correlating with neutrophilic infiltration, as well as upon LPS-induced ALI, an animal model characterized by neutrophilic infiltration. Surprisingly, and non withstanding the limitations of the study and the observed trends, Lcn2-/- mice were found to still develop BLM- or LPS-induced pulmonary inflammation and fibrosis, thus questioning a major pathogenic role for Lcn2 in mice. However, LCN2 qualifies as a surrogate biomarker of pulmonary inflammation and a possible indicator of compromised pulmonary functions, urging for larger studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute lung injury | |
| 650 | 4 | |a bleomycin (BLM) | |
| 650 | 4 | |a idiopathic pulmonary fibrosis (IPF) | |
| 650 | 4 | |a lipocalin-2 (LCN2) | |
| 650 | 4 | |a transcriptomics | |
| 700 | 1 | |a Fanidis, Dionysios |e verfasserin |4 aut | |
| 700 | 1 | |a Tsitoura, Eliza |e verfasserin |4 aut | |
| 700 | 1 | |a Kanellopoulou, Paraskevi |e verfasserin |4 aut | |
| 700 | 1 | |a Barbayianni, Ilianna |e verfasserin |4 aut | |
| 700 | 1 | |a Ntatsoulis, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Touloumi, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Gramenoudi, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Karampitsakos, Theodoros |e verfasserin |4 aut | |
| 700 | 1 | |a Tzouvelekis, Argyrios |e verfasserin |4 aut | |
| 700 | 1 | |a Antoniou, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Aidinis, Vassilis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in medicine |d 2014 |g 10(2023) vom: 18., Seite 1195501 |w (DE-627)NLM245390847 |x 2296-858X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g day:18 |g pages:1195501 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fmed.2023.1195501 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |b 18 |h 1195501 | ||